Comparative Pharmacology
Head-to-head clinical analysis: CORTISONE ACETATE versus DEFLAZACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTISONE ACETATE versus DEFLAZACORT.
CORTISONE ACETATE vs DEFLAZACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
None Documented
None Documented
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderate30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid
Deflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."